secwatch.observer — SEC 8-K summary
======================================

Issuer:     Quince Therapeutics, Inc. (QNCX)
CIK:        0001662774
Form:       8-K/A
Filed at:   2026-05-18T20:20:26+00:00
Accession:  0001193125-26-228956
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Quince reports positive Phase 2a LAM-001 data in PH-ILD; 6MWD +67.4m, PVR -33.9%
--------------------------------------------------------------------------------

- Phase 2a open-label trial in PH-ILD (n=4 evaluable) on stable treprostinil showed 6MWD increase of 67.4 meters and PVR reduction of 33.9% at 24 weeks.
- All evaluable PH-ILD patients improved from Functional Class III to II by Week 24; LAM-001 was generally well tolerated.
- Phase 2b trial in PH-ILD to begin mid-2026 with topline data expected in Q1 2028.
- 8-K/A corrects sign errors in original press release table for PVR percentages (now shown as -35.3% and -33.9% for evaluable population and PH-ILD subgroup respectively).
- LAM-001 is an inhaled mTOR inhibitor acquired from Orphai Therapeutics; Quince plans to continue development in PH-ILD.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1662774/000119312526228956/0001193125-26-228956-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1662774/000119312526228956/d135388d8ka.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-228956

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer